Background and Objective. Since 1988 the AIEOP has used BFM-based chemotherapy for childhood ALL. Current organization and results and role of cranial irradiation in the AIEOP-ALL 91 study are reported. Design and Methods. From 1991 to 1995, 1194 children (<15 years) with non-B ALL, were enrolled and assigned to the standard risk [SR: age >1 year, non-T-ALL, BFM risk factor (RF) <0.8], intermediate risk (IR: RF greater than or equal to 0.8 but <1.7, or with RF <0.8 and age <1 year, or T-ALL), or high risk [HR: RF greater than or equal to 1.7, or t(9;22), or t(4;11) or prednisone poor response or late response or CNS involvement] groups. All patients received initially protocol Ia. Thereafter SR patients received HD-MTX 2 g/m(2), a modified protocol II, and continuation therapy with triple intrathecal chemotherapy (TIT); IR patients received protocol Ib, HD-MTX 5 g/m(2), protocol II and continuation therapy with TIT; HR patients received 9 polychemotherapy blocks, cranial irradiation and continuation therapy. Duration of treatment was 24 months. A randomized study was conducted to evaluate the impact of high-dose asparaginase in non high risk patients: the results of this study cannot be disclosed yet. Results. One thousand one hundred and fifty-two (95.5%) patients achieved CR. Overall EFS (SE) at 5-years was 71.0% (1.4), with a survival of 80.3% (1.3). Relapse occurred in 262 children (21.9%), either in the marrow (n=192 isolated and 32 with other sites, 18.7%), in the CNS (n=18, 1.5%), or elsewhere (n=20, 1.7%). 5-year EFS (SE) was 83.3% (2.4) in SR, 74.7% (1.8) in IR, and 39.7% (3.5) in HR groups, respectively. Interpretation and Conclusions. Overall cure rate was higher than in the previous AIEOP-ALL 88 study. Treatment intensification with polychemotherapy blocks did not improve results in HR. Cranial irradiation can be safely omitted In over 80% of children treated with BFM based chemotherapy

Conter, V., Aricò, M., Valsecchi, M., Rizzari, C., Testi, A., Miniero, R., et al. (1998). Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica. HAEMATOLOGICA, 83(9), 791-799.

Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica

VALSECCHI, MARIA GRAZIA;Rizzari, C;BIONDI, ANDREA;
1998

Abstract

Background and Objective. Since 1988 the AIEOP has used BFM-based chemotherapy for childhood ALL. Current organization and results and role of cranial irradiation in the AIEOP-ALL 91 study are reported. Design and Methods. From 1991 to 1995, 1194 children (<15 years) with non-B ALL, were enrolled and assigned to the standard risk [SR: age >1 year, non-T-ALL, BFM risk factor (RF) <0.8], intermediate risk (IR: RF greater than or equal to 0.8 but <1.7, or with RF <0.8 and age <1 year, or T-ALL), or high risk [HR: RF greater than or equal to 1.7, or t(9;22), or t(4;11) or prednisone poor response or late response or CNS involvement] groups. All patients received initially protocol Ia. Thereafter SR patients received HD-MTX 2 g/m(2), a modified protocol II, and continuation therapy with triple intrathecal chemotherapy (TIT); IR patients received protocol Ib, HD-MTX 5 g/m(2), protocol II and continuation therapy with TIT; HR patients received 9 polychemotherapy blocks, cranial irradiation and continuation therapy. Duration of treatment was 24 months. A randomized study was conducted to evaluate the impact of high-dose asparaginase in non high risk patients: the results of this study cannot be disclosed yet. Results. One thousand one hundred and fifty-two (95.5%) patients achieved CR. Overall EFS (SE) at 5-years was 71.0% (1.4), with a survival of 80.3% (1.3). Relapse occurred in 262 children (21.9%), either in the marrow (n=192 isolated and 32 with other sites, 18.7%), in the CNS (n=18, 1.5%), or elsewhere (n=20, 1.7%). 5-year EFS (SE) was 83.3% (2.4) in SR, 74.7% (1.8) in IR, and 39.7% (3.5) in HR groups, respectively. Interpretation and Conclusions. Overall cure rate was higher than in the previous AIEOP-ALL 88 study. Treatment intensification with polychemotherapy blocks did not improve results in HR. Cranial irradiation can be safely omitted In over 80% of children treated with BFM based chemotherapy
Articolo in rivista - Articolo scientifico
Adolescent; Risk; Chromosome Aberrations; Dexamethasone; 6-Mercaptopurine; Asparaginase; Methotrexate; Leucovorin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Daunorubicin; Thioguanine; Child; Remission Induction; Doxorubicin; Combined Modality Therapy; Treatment Outcome; Prognosis; Male; Infant; Female; Child, Preschool; Italy; Disease-Free Survival; Cyclophosphamide; Humans; Cytarabine; Bone Marrow Transplantation; Antineoplastic Combined Chemotherapy Protocols; Vincristine; Cranial Irradiation
English
1998
83
9
791
799
none
Conter, V., Aricò, M., Valsecchi, M., Rizzari, C., Testi, A., Miniero, R., et al. (1998). Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica. HAEMATOLOGICA, 83(9), 791-799.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/21628
Citazioni
  • Scopus 56
  • ???jsp.display-item.citation.isi??? 56
Social impact